According to Fact.MR’s research report on the global peptide based infection therapeutics market, the market is anticipated to show a robust growth rate during the forecasted period of 2017-2022 and expected to reflect a value a bit less than US$ 1.5 Bn. As antibiotic resistance soar globally, there is an escalating pressure to come up with novel classes of antimicrobial compounds to fight infectious diseases. The application of slow release or efficient targeting drug delivery system in line with a therapeutic peptide may mitigate or reduce the need for excessive modification. As such, liposomal systems provide increased circulatory time of the encapsulated therapeutics and at the same time allowing targeting, at sites of infection or tumor growth. This has been used for the delivery of anticancer drugs which may have benefits for delivery of peptides therapeutics. In order to effectively treat an infection, manufacturers are focusing on composition or chemical modification, t...